Outcome of the Board Meeting dated May 16, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.8 pts more than Nifty Microcap 250 and 5.0 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board approved audited financial results for Q4 and FY ended March 31, 2025 with an unmodified (clean) opinion from statutory auditor Sarda Soni Associates LLP. FY25 revenue from operations jumped to ₹2,199.90 lakhs from ₹1,320.49 lakhs in FY24, a growth of about 66.6%. The company swung from a loss after tax of ₹267.22 lakhs in FY24 to a profit of ₹207.26 lakhs in FY25, with EPS turning positive at ₹2.01 vs negative ₹2.60 earlier. Operating cash flow improved to ₹187.70 lakhs. The Board also appointed M/s. Nilesh A. Pradhan & Co. LLP as Secretarial Auditor (5 years) and M/s. Vishal J Bhanushali & Associates as Internal Auditor (FY26), and approved re-appointment of Dr. Pankaj Shah as MD & CEO for 3 years from August 1, 2025, subject to shareholder approval via postal ballot (record date June 6, 2025).
Strong turnaround story — revenue grew ~67%, company returned to profitability from a prior-year loss, and operating cash flow turned firmly positive, which is positive for shareholders. Re-appointment of the long-tenured MD provides continuity; the postal ballot for shareholder approval is the next event to watch.